Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study

SIMPLE SUMMARY: In the last years, treatments for recurrent glioblastoma patients have shown limited efficacy in terms of OS. In the REGOMA trial, regorafenib demonstrated encouraging results in this setting of population. Indeed, in this randomized, phase 2 study the OS was significantly improved i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardi, Giuseppe, Caccese, Mario, Padovan, Marta, Cerretti, Giulia, Pintacuda, Giovanna, Manara, Renzo, Di Sarra, Francesca, Zagonel, Vittorina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471957/
https://www.ncbi.nlm.nih.gov/pubmed/34572958
http://dx.doi.org/10.3390/cancers13184731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471957/
https://www.ncbi.nlm.nih.gov/pubmed/34572958
http://dx.doi.org/10.3390/cancers13184731

Ejemplares similares